Aviado · Research
Longevity Daily
Sunday, June 7, 2026
Listen
Today's Brief
The week's biggest longevity story is a sobering one: semaglutide's Phase 3 EVOKE trial in Alzheimer's disease came up short despite years of promising observational signals — a critical reminder that association isn't causation in longevity medicine. Separately, a popular anti-aging drug combination triggered myelin damage in mice, a warning the biohacker community shouldn't dismiss. On the more actionable front, new data confirm vitamin K2 (MK-7) can mitigate menopause-related vascular damage, Fight Aging! surfaces a compelling bat-biology framework for human longevity, and Pharmacy Times delivers the Neuriva evidence check this widely used supplement has long needed.
10 stories2 peer-reviewed2 trials
Cognitive Health & Neuroprotection
Semaglutide's Phase 3 Alzheimer's Trial Comes Up Short — Despite Years of Promise
The Phase 3 EVOKE trial of semaglutide (Ozempic/Wegovy) for Alzheimer's disease has failed to meet its primary endpoints, ending one of the most anticipated tests of GLP-1 drugs in neurodegeneration. The trial design was rigorous — biomarker-rich endpoints, CSF markers, long treatment durations — making the null result hard to dismiss as a design flaw. Earlier real-world data had shown a 40–70% lower Alzheimer's risk with semaglutide versus other diabetes drugs, a gap between association and causation that this trial makes starkly clear. For the millions taking GLP-1 drugs partly for brain health, this is a significant and necessary reality check.
Read more →A Popular Anti-Aging Drug Combination Triggers Brain Damage in Mice
A new report reveals that a popular anti-aging drug combination caused severe myelin damage in mice — a finding with direct implications for the longevity biohacker community that routinely stacks multiple longevity compounds. The researchers note the findings may also shed light on MS-like demyelinating conditions, suggesting an unexpected mechanistic overlap worth monitoring. This is a mouse study, and the specific compounds are detailed in the full article, but it warrants serious attention given how commonly certain anti-aging stacks are used off-label.
Read more →Neuriva Is One of America's Best-Selling Brain Supplements — Here's What the Evidence Actually Shows
Neuriva is marketed to support five cognitive functions — memory, accuracy, learning, focus, and concentration — and is endorsed by neuroscientist and actress Mayim Bialik, but Pharmacy Times' clinical review finds the evidence behind its key ingredients is thinner than its marketing suggests. Phosphatidylserine and coffee fruit extract carry some mechanistic plausibility, but the FDA has not evaluated any of the product's claims. If you take Neuriva or are considering it, this is the evidence-based breakdown worth reading before your next purchase.
Read more →Supplements & Compounds
Vitamin K2 (MK-7) Mitigates Menopause-Related Blood Pressure Damage in New Trial Analysis
A new post-hoc analysis of the MenaQ7 supplementation trial finds that daily vitamin K2 as MK-7 can meaningfully offset the vascular damage menopause inflicts on blood pressure, with the study coordinator concluding that while menopause "negatively affects vascular health," MK-7 supplementation can "mitigate these effects." The findings support K2's cardiovascular role well beyond its established bone-health benefits, and are particularly relevant for women approaching or in menopause who are already weighing supplementation options. Because this is a post-hoc analysis, causal conclusions are limited — but it adds meaningfully to a growing K2 evidence base.
Read more →Metformin Shows a Survival Hint in Prostate Cancer — But Falls Short of Statistical Significance
After 60 months of follow-up, a large trial found that adding metformin to standard care in metastatic hormone-sensitive prostate cancer improved median survival by 5.6 months (67.4 vs. 61.8 months) with fewer total deaths — but the difference fell short of statistical significance. For longevity enthusiasts taking metformin off-label as an anti-aging drug, the data are mixed: a tantalizing numerical signal without a definitive effect, and in a specific cancer population that may not generalize to healthy aging. The trial adds to a growing picture of metformin's context-dependent and often modest real-world impact.
Read more →Research & Papers
An Old Antidepressant Drug Extended Lifespan in Aging Mice by Restoring Calcium Balance
Publishing in Nature Communications, researchers show that disrupted calcium homeostasis is a core driver of both accelerated aging (progeria) and natural aging in mice, triggering a cascade that damages DNA and activates the cGAS-STING inflammatory pathway. Strikingly, mianserin — a decades-old tetracyclic antidepressant — significantly extended lifespan in naturally aged mice by blocking serotonin receptors HTR2B/2C to lower intracellular calcium levels. This is mouse data and mianserin carries its own side-effect profile, but the calcium homeostasis pathway represents a compelling new target for longevity therapeutics.
Read more →Not All Zombie Cells Are Equal — Scientists Identify Which Senescent Cells Do the Most Damage
New research challenges the prevailing "nuke all zombie cells" mentality in the senolytic space, showing that not all senescent cells are harmful and that indiscriminate clearance risks eliminating beneficial ones. Emerging CAR-T-based approaches targeting specific surface markers — uPAR and NKG2DL — on pathogenic senescent cells are in early clinical development, offering a more targeted alternative to broad-spectrum senolytics. For readers taking quercetin, fisetin, or other OTC senolytics, this is important context: precision may eventually matter more than volume.
Read more →What Bats Can Teach Us About Living Longer: A New Roadmap for Longevity Biology
Fight Aging! covers a new paper mapping the biology behind bats' extraordinary longevity — they outlive comparably sized mammals by decades — identifying three key mechanisms: efficient mitochondrial stress defenses, superior control over chronic inflammation, and enhanced DNA damage repair. Researchers have already begun transplanting some of these mechanisms into mice, with early anti-inflammatory results, and the paper proposes bat biology as a structured roadmap for human longevity interventions. It's foundational science, but the kind of systems-level thinking that has historically preceded the most durable breakthroughs.
Read more →Lifestyle & Nutrition
Time-Restricted Eating Improves Healthspan in Aging Mice — But Only When Timed Right
A new perspective in Nature Aging highlights evidence that time-restricted feeding (TRF) improves multiple markers of healthspan in aging mice, but with a critical nuance: the benefits appear heavily dependent on circadian alignment, meaning meal timing relative to the body's active phase matters as much as the length of the eating window. The practical implication for TRF practitioners is a meaningful refinement — eating in the early active phase (morning for humans) rather than any arbitrary 8-hour window may determine whether you capture the full metabolic benefit. Human equivalents are still being established; this paper focuses on animal data.
Read more →Industry & Policy
Serena Williams Is Taking GLP-1 Drugs for Performance — What It Signals for Longevity Medicine
Business Insider examines what Serena Williams' high-profile GLP-1 endorsement — starring in a Super Bowl ad for telehealth prescriber Ro — signals for the future of these compounds as performance and healthspan tools, not just weight-loss drugs. The piece tracks how GLP-1 narratives are shifting from obesity treatment toward vitality, movement quality, and longevity, a reframe with significant market and regulatory implications. Worth reading alongside today's EVOKE trial story: as GLP-1s gain cultural momentum, the science of their specific longevity benefits remains very much a work in progress.
Read more →